Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,501.65 0.00 0.00%
S&P 500 1,878.61 3.22 0.17%
NASDAQ 4,148.34 21.37 0.52%
Ticker Volume Price Price Delta
STOXX 50 3,189.81 13.84 0.44%
FTSE 100 6,703.00 28.26 0.42%
DAX 9,548.68 4.49 0.05%
Ticker Volume Price Price Delta
NIKKEI 14,424.00 19.01 0.13%
TOPIX 1,169.57 4.67 0.40%
HANG SENG 22,254.80 -308.00 -1.37%

Clinical Study Results, Approvals, Financial Results, New Facilities, and Business Expansions - Research Report on Merck,



  Clinical Study Results, Approvals, Financial Results, New Facilities, and
   Business Expansions - Research Report on Merck, UnitedHealth Group, NPS
                    Pharmaceuticals, Abbott, and Medtronic

Editor Note: For more information about this release, please scroll to bottom.

  PR Newswire

  NEW YORK, November 11, 2013

NEW YORK, November 11, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Merck &
Co., Inc. (NYSE: MRK), UnitedHealth Group Inc. (NYSE: UNH), NPS
Pharmaceuticals, Inc. (NASDAQ: NPSP), Abbott Laboratories (NYSE: ABT), and
Medtronic, Inc. (NYSE: MDT). Today's readers may access these reports free of
charge - including full price targets, industry analysis and analyst ratings -
via the links below.

Merck & Co., Inc. Research Report

On November 4, 2013, Merck & Co., Inc. (Merck) announced that in the Phase III
efficacy study, its investigational 9-valent HPV vaccine (V503) prevented
approximately 97.0% of cervical, vaginal and vulvar pre-cancers caused by HPV
types 31, 33, 45, 52, and 58. The Company stated that V503 also generated
immune responses to HPV types 6, 11, 16, and 18 that were non-inferior to
those generated by GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11,
16, and 18) Vaccine, Recombinant].  Roger M. Perlmutter, M.D., Ph.D.,
President of Merck Research Laboratories, commented, "With our ongoing
commitment to research, we are building upon the success obtained with
GARDASIL, and we expect to submit a Biologics License Application for V503 to
the U.S. Food and Drug Administration before the end of 2013." The Full
Research Report on Merck & Co., Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

[ http://www.analystscorner.com/r/full_research_report/430d_MRK ]

--

UnitedHealth Group Inc. Research Report

On October 30, 2013, UnitedHealth Group Inc. (UnitedHealth Group) reported
that UnitedHealthcare Community Plan - a business unit of its subsidiary,
UnitedHealthcare, has expanded its service area to include eight New York
State counties namely: Albany, Chautauqua, Chemung, Columbia, Essex, Genesee,
Niagara, and St. Lawrence, where it offers the New York State Medicaid, Family
Health Plus and Child Health Plus plans. The Company informed that
UnitedHealthcare's New York State Medicaid, Family Health Plus, and Child
Health Plus plans are now available in New York City, on Long Island, in the
Hudson Valley, and throughout Central and Western New York. UnitedHealth Group
added that with this expansion, UnitedHealthcare Community Plans are now
available in 34 New York counties. The Full Research Report on UnitedHealth
Group Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

[ http://www.analystscorner.com/r/full_research_report/73e5_UNH ]

--

NPS Pharmaceuticals, Inc. Research Report

On November 6, 2013, NPS Pharmaceuticals, Inc. (NPS Pharmaceuticals) reported
its Q3 2013 financial results. Total revenues increased 45.1% YoY to $39.2
million during the quarter. Net loss was $1.1 million or $0.01 per diluted
share in Q3 2013, compared to $3.3 million or $0.04 per diluted share in Q3
2012. Commenting on the results, Francois Nader, M.D., President and CEO at
NPS Pharmaceuticals, said, "We are excited by the continued success of the
Gattex launch in the U.S. We are seeing strong demand and sales have exceeded
our expectations so far with 235 patients now on Gattex. We are also pleased
to raise our full-year net sales guidance to $28 to $32 million given the
favorable results and trends we have seen so far." The Full Research Report on
NPS Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings
and price targets - is available to download free of charge at:

[ http://www.analystscorner.com/r/full_research_report/441a_NPSP ]

--

Abbott Laboratories Research Report

On November 6, 2013, Abbott Laboratories (Abbott) together with its
foundation, the Abbott Fund, and Partners in Health (PIH) announced the
opening of a new nutrition production facility to produce "Nourimanba," a
life-saving treatment for severe malnutrition in children, in Central Plateau
in Haiti. The Company stated that the first shipments of Nourimanba produced
at the facility have been distributed in PIH's clinics in the region, and are
already being used to provide effective treatment for children. Ophelia Dahl,
PIH Co-Founder and Executive Director, commented, "After several years of
close collaboration, we are excited to achieve this significant milestone in
our partnership with Abbott and the Abbott Fund. Producing Nourimanba at the
new facility will help PIH and Zanmi Lasante to continue providing free,
high-quality treatment for children at our clinics across the region." The
Full Research Report on Abbott Laboratories - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

[ http://www.analystscorner.com/r/full_research_report/05c1_ABT ]

--

Medtronic, Inc. Research Report

On November 5, 2013, Medtronic, Inc. (Medtronic) announced that the U.S. Food
and Drug Administration (FDA) has approved an Investigational Device Exemption
(IDE), allowing the Company to initiate SYMPLICITY HTN-4, the first randomized
trial to investigate renal denervation for the treatment of moderate
uncontrolled hypertension in U.S. patients. Medtronic reported that the study
will evaluate Symplicity™ renal denervation system in patients with moderate
uncontrolled hypertension (systolic blood pressure greater than or equal to
140 and less than 160 mm HG, despite treatment with three or more
anti-hypertensive medications of different classes). Nina Goodheart, Vice
President, General Manager, Renal Denervation, Medtronic, commented,
"SYMPLICITY HTN-4 builds upon our rigorous clinical evaluation of the
Symplicity renal denervation system designed to carefully and progressively
develop the clinical evidence platform for the treatment of hypertension."
According to the Company, SYMPLICITY HTN-4, is Medtronic's second randomized,
controlled renal denervation clinical trial in the United States. The Full
Research Report on Medtronic, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at:

[ http://www.analystscorner.com/r/full_research_report/bc94_MDT ]

----

EDITOR NOTES:

 1. This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
 2. Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
 3. This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
 4. If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com .
 5. For any urgent concerns or inquiries , please contact us at
    compliance@EquityNewsNetwork.com .
 6. Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

Contact: CONTACT PERSON: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North
America).
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement